NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Rhea-AI Summary
NextCure (Nasdaq: NXTC) and Simcere Zaiming initiated the dose optimization portion of the Phase 1 study of SIM0505, an investigational CDH6-targeting ADC, focused initially on patients with platinum-resistant ovarian cancer (PROC).
The program will expand U.S. and China trial sites and add sites in Canada and Europe. Phase 1 data readout is planned for ASCO 2026.
Positive
- Initiation of dose optimization for SIM0505 in PROC
- Planned Phase 1 data readout at ASCO 2026
- Expanded clinical footprint: increased sites in U.S. and China and new sites in Canada and Europe
Negative
- SIM0505 remains in Phase 1; no registrational data yet
- No efficacy or safety outcomes disclosed in this announcement
Key Figures
Market Reality Check
Peers on Argus
NXTC was up 1.63% with peers like BIVI and IMNN also moving up around 3–4%, pointing to broader biotech strength rather than a purely stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | ASCO data announcement | Positive | -6.2% | Planned Phase 1 SIM0505 data poster presentation at ASCO 2026. |
| Apr 07 | Regulatory designation | Positive | +0.9% | FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer. |
| Mar 31 | Conference abstract | Positive | -1.4% | SIM0505 abstract acceptance for ASCO 2026 presentation in solid tumors. |
| Mar 05 | Earnings and update | Neutral | -2.9% | Full-year 2025 results and guidance on SIM0505 and LNCB74 timelines. |
| Jan 23 | Pipeline update | Neutral | -5.8% | Business update on ADC programs and cash runway into 1H 2027. |
Recent SIM0505-related announcements, including ASCO appearances and Fast Track status, have often seen muted or negative next-day reactions despite positive clinical momentum.
Over the past few months, NXTC has repeatedly highlighted progress for SIM0505, including ASCO 2026 abstract acceptance on Mar 31, 2026 and Fast Track designation on Apr 7, 2026. Business updates on Jan 23 and full-year 2025 results on Mar 5 emphasized a focused ADC pipeline and expected Phase 1 readouts in Q2 2026. Today’s initiation of dose optimization operationalizes earlier guidance about moving SIM0505 into this next Phase 1 stage.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 26, 2025 registers 2,523,477 shares of common stock for resale, including 1,815,049 shares underlying pre-funded warrants from a prior private placement that raised $21.5 million. NextCure receives no proceeds from resale of these registered shares, and only about $1,815 if all pre-funded warrants are exercised.
Market Pulse Summary
This announcement confirms that SIM0505 has advanced into the dose optimization stage of its Phase 1 study in platinum-resistant ovarian cancer, with a Phase 1 readout targeted for ASCO 2026. It follows prior disclosures about Fast Track designation and planned timelines, showing execution against earlier guidance. Investors may track future updates on dose selection, geographic trial expansion, and the upcoming ASCO data to contextualize SIM0505’s role within NextCure’s focused ADC pipeline.
Key Terms
antibody drug conjugate medical
adc medical
topoisomerase 1 inhibitor medical
platinum-resistant ovarian cancer medical
AI-generated analysis. Not financial advice.
- Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC)
- Phase 1 data readout to be presented at ASCO 2026
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
“Initiation of dose optimization highlights the promise of our novel CDH6-directed ADC and our focus on bringing SIM0505 to patients as quickly as possible. The dose optimization study is intended to help finalize dose selection and further de-risk advancement toward registrational studies. Additionally, we are accelerating development of the program by increasing the number of U.S. and China trial sites and expanding our clinical site footprint into Canada and Europe,” said Michael Richman, President and CEO of NextCure. “We look forward to presenting Phase 1 data at the upcoming 2026 American Society of Clinical Oncology (ASCO) conference as we continue to build momentum in the program.”
About SIM0505
SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer with an emphasis on platinum resistant ovarian cancer. The Food and Drug Administration granted Fast Track to SIM0505 for platinum-resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu®, COSELA®, Enweida®, Endostar®, and Enlituo®. The Company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies which may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
